The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC)

At Dynacare, our vision is to be Canada’s health and wellness solutions leader. As part of our commitment to you, our partners in care, Dynacare will be reporting salivary gland cytology using The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) starting on October 11^th, 2021.

The Milan System for Reporting Salivary Gland Cytopathology has been developed by an international consortium of experienced healthcare professionals. It is an evidence-based system derived from literature which correlates diagnostic categories with risk of malignancy and clinical management strategies. The main objective of this change to The Milan System for Reporting Salivary Gland Cytopathology System is to emphasize risk of malignancy by utilizing a standardized diagnostic framework for reporting.¹   The Milan System for Reporting Salivary Gland Cytopathology is endorsed by the Canadian Society of Cytopathology.² The establishment of a classification system for reporting salivary gland FNA represents an essential step towards improving the overall effectiveness of salivary gland FNA, leading to improved patient care.

Dynacare is committed to providing the highest quality and value to our partners and to enhance the overall healthcare system. If you would like to further discuss, please feel free to contact Tamar Webster at 800.668.2714 x5256 or webstert@dynacare.ca. 

We appreciate your support and look forward to working with you as we strive to enhance the quality of our service for all our partners.

Partner Update - The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC)